Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

SciClone Pharmaceuticals, Inc. SCLN NASDAQ

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • USD

SharesGrow Score
80/100
5/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

SciClone Pharmaceuticals, Inc. (SCLN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $11.15. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Financials: revenue is $160M, +8.2%/yr average growth. Net income is $31M, growing at +50.4%/yr. Net profit margin is 19.2% (healthy). Gross margin is 85.7% (-0.4 pp trend).

Balance sheet: total debt is $0 against $215M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.4 (strong liquidity). Debt-to-assets is 0%. Total assets: $242M.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 83/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 54/100 (Partial), Future ?/100 (Fail), Income 70/100 (Pass).

SCLN SharesGrow Score Overview

80/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 83/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 54/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 70/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SCLN

✓
VALUE Pass
75/100
SCLN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
83/100
SCLN: +8.2%/yr revenue is, +50.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
SCLN: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet SCLN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 7.4 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
54/100
SCLN: Gross margin is 85.7% (-0.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 54/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✓
INCOME Pass
70/100
SCLN: Net profit margin is 19.2%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range11.425-8.55
Volume2.22M
Avg Volume (30D)449.6K
Beta (1Y)1.71
Share Statistics
EPS (TTM)0.61
Shares Outstanding$50.24M
IPO Date1992-03-17
Financial Highlights & Ratios
Revenue (TTM)$160.1M
Gross Profit$137.2M
EBITDA$35.12M
Net Income$30.73M
Operating Income$33.24M
Total Cash$135.19M
Net Debt$-134.4M
Total Assets$241.9M
Price / Earnings (P/E)18.3
Analyst Forecast
Company Info
ExchangeNASDAQ
CurrencyUSD

Price Chart

Track all markets on TradingView
SCLN
SciClone Pharmaceuticals, Inc.  ·  NASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message